167 related articles for article (PubMed ID: 37947157)
1. A phase 2 study of MK-2206 in patients with incurable adenoid cystic carcinoma (Alliance A091104).
Ho AL; Foster NR; Deraje Vasudeva S; Katabi N; Antonescu CR; Frenette GP; Pfister DG; Erlichman C; Schwartz GK
Cancer; 2024 Mar; 130(5):702-712. PubMed ID: 37947157
[TBL] [Abstract][Full Text] [Related]
2. A phase II study of axitinib (AG-013736) in patients with incurable adenoid cystic carcinoma.
Ho AL; Dunn L; Sherman EJ; Fury MG; Baxi SS; Chandramohan R; Dogan S; Morris LG; Cullen GD; Haque S; Sima CS; Ni A; Antonescu CR; Katabi N; Pfister DG
Ann Oncol; 2016 Oct; 27(10):1902-8. PubMed ID: 27566443
[TBL] [Abstract][Full Text] [Related]
3. MYB rearrangement and clinicopathologic characteristics in head and neck adenoid cystic carcinoma.
Rettig EM; Tan M; Ling S; Yonescu R; Bishop JA; Fakhry C; Ha PK
Laryngoscope; 2015 Sep; 125(9):E292-9. PubMed ID: 25963073
[TBL] [Abstract][Full Text] [Related]
4. A phase II study of sorafenib in recurrent and/or metastatic salivary gland carcinomas: Translational analyses and clinical impact.
Locati LD; Perrone F; Cortelazzi B; Bergamini C; Bossi P; Civelli E; Morosi C; Lo Vullo S; Imbimbo M; Quattrone P; Dagrada GP; Granata R; Resteghini C; Mirabile A; Alfieri S; Orlandi E; Mariani L; Saibene G; Pilotti S; Licitra L
Eur J Cancer; 2016 Dec; 69():158-165. PubMed ID: 27821319
[TBL] [Abstract][Full Text] [Related]
5. Targeting the Oncogenic Transcriptional Regulator MYB in Adenoid Cystic Carcinoma by Inhibition of IGF1R/AKT Signaling.
Andersson MK; Afshari MK; Andrén Y; Wick MJ; Stenman G
J Natl Cancer Inst; 2017 Sep; 109(9):. PubMed ID: 28954282
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
Mitani Y; Li J; Rao PH; Zhao YJ; Bell D; Lippman SM; Weber RS; Caulin C; El-Naggar AK
Clin Cancer Res; 2010 Oct; 16(19):4722-31. PubMed ID: 20702610
[TBL] [Abstract][Full Text] [Related]
7. Study of MYB-NFIB chimeric gene expression, tumor angiogenesis, and proliferation in adenoid cystic carcinoma of salivary gland.
Ono J; Okada Y
Odontology; 2018 Jul; 106(3):238-244. PubMed ID: 29243184
[TBL] [Abstract][Full Text] [Related]
8. MYB-NFIB gene fusions identified in archival adenoid cystic carcinoma tissue employing NanoString analysis: an exploratory study.
McIntyre JB; Ko JJ; Siever J; Chan AMY; Simpson RHW; Hao D; Lau HY
Diagn Pathol; 2019 Jul; 14(1):78. PubMed ID: 31301736
[TBL] [Abstract][Full Text] [Related]
9. Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms.
Brill LB; Kanner WA; Fehr A; Andrén Y; Moskaluk CA; Löning T; Stenman G; Frierson HF
Mod Pathol; 2011 Sep; 24(9):1169-76. PubMed ID: 21572406
[TBL] [Abstract][Full Text] [Related]
10. UM-HACC-2A: MYB-NFIB fusion-positive human adenoid cystic carcinoma cell line.
Warner KA; Oklejas AE; Pearson AT; Zhang Z; Wu W; Divi V; Rodriguez-Ramirez C; Castilho RM; Polverini PJ; Nör JE
Oral Oncol; 2018 Dec; 87():21-28. PubMed ID: 30527239
[TBL] [Abstract][Full Text] [Related]
11. MYB and MYBL1 in adenoid cystic carcinoma: diversity in the mode of genomic rearrangement and transcripts.
Togashi Y; Dobashi A; Sakata S; Sato Y; Baba S; Seto A; Mitani H; Kawabata K; Takeuchi K
Mod Pathol; 2018 Jun; 31(6):934-946. PubMed ID: 29410490
[TBL] [Abstract][Full Text] [Related]
12. [Correlation of MYB/NFIB gene fusion with the grade and prognosis of head and neck adenoid cystic carcinoma and the concordance of two detection methods].
Zhu YL; Li Y; Mu JL; Liu WC; Li X; Lu HZ
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):149-154. PubMed ID: 38281782
[No Abstract] [Full Text] [Related]
13. Prognostic significance of 1p36 locus deletion in adenoid cystic carcinoma of the salivary glands.
Šteiner P; Andreasen S; Grossmann P; Hauer L; Vaněček T; Miesbauerová M; Santana T; Kiss K; Slouka D; Skálová A
Virchows Arch; 2018 Oct; 473(4):471-480. PubMed ID: 29619555
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors.
Wong SJ; Karrison T; Hayes DN; Kies MS; Cullen KJ; Tanvetyanon T; Argiris A; Takebe N; Lim D; Saba NF; Worden FP; Gilbert J; Lenz HJ; Razak AR; Roberts JD; Vokes EE; Cohen EE
Ann Oncol; 2016 Feb; 27(2):318-23. PubMed ID: 26598548
[TBL] [Abstract][Full Text] [Related]
15. MYB, MYBL1, MYBL2 and NFIB gene alterations and MYC overexpression in salivary gland adenoid cystic carcinoma.
Fujii K; Murase T; Beppu S; Saida K; Takino H; Masaki A; Ijichi K; Kusafuka K; Iida Y; Onitsuka T; Yatabe Y; Hanai N; Hasegawa Y; Inagaki H
Histopathology; 2017 Nov; 71(5):823-834. PubMed ID: 28594149
[TBL] [Abstract][Full Text] [Related]
16. MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation.
West RB; Kong C; Clarke N; Gilks T; Lipsick JS; Cao H; Kwok S; Montgomery KD; Varma S; Le QT
Am J Surg Pathol; 2011 Jan; 35(1):92-9. PubMed ID: 21164292
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of lapatinib in recurrent or metastatic epidermal growth factor receptor and/or erbB2 expressing adenoid cystic carcinoma and non adenoid cystic carcinoma malignant tumors of the salivary glands.
Agulnik M; Cohen EW; Cohen RB; Chen EX; Vokes EE; Hotte SJ; Winquist E; Laurie S; Hayes DN; Dancey JE; Brown S; Pond GR; Lorimer I; Daneshmand M; Ho J; Tsao MS; Siu LL
J Clin Oncol; 2007 Sep; 25(25):3978-84. PubMed ID: 17761983
[TBL] [Abstract][Full Text] [Related]
18. Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.
Mitani Y; Rao PH; Futreal PA; Roberts DB; Stephens PJ; Zhao YJ; Zhang L; Mitani M; Weber RS; Lippman SM; Caulin C; El-Naggar AK
Clin Cancer Res; 2011 Nov; 17(22):7003-14. PubMed ID: 21976542
[TBL] [Abstract][Full Text] [Related]
19. Adenoid cystic carcinoma of the lacrimal gland: MYB gene activation, genomic imbalances, and clinical characteristics.
von Holstein SL; Fehr A; Persson M; Therkildsen MH; Prause JU; Heegaard S; Stenman G
Ophthalmology; 2013 Oct; 120(10):2130-8. PubMed ID: 23725736
[TBL] [Abstract][Full Text] [Related]
20. Recurrent Fusions in MYB and MYBL1 Define a Common, Transcription Factor-Driven Oncogenic Pathway in Salivary Gland Adenoid Cystic Carcinoma.
Brayer KJ; Frerich CA; Kang H; Ness SA
Cancer Discov; 2016 Feb; 6(2):176-87. PubMed ID: 26631070
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
